Core Viewpoint - Dongfeng Group Co., Ltd. has announced its application to the Hong Kong Stock Exchange for the withdrawal of its H-shares listing status, which has been approved and will take effect on March 18, 2026 [1] Group 1 - The company has received approval from the Hong Kong Stock Exchange for the delisting of its H-shares [1] - The effective date for the delisting is set for March 18, 2026, at 4:00 PM [1]

Core Viewpoint - China National Pharmaceutical Group (国药控股) announced the preliminary performance report for China National Pharmaceutical Group Co., Ltd. (国药一致) for the fiscal year 2025, highlighting a mixed financial performance with a decline in revenue but significant growth in profits [1] Financial Performance Summary - The total operating revenue for China National Pharmaceutical Group Co., Ltd. reached 73.416 billion yuan, representing a year-on-year decrease of 1.29% [1] - Operating profit amounted to 1.513 billion yuan, showing a substantial year-on-year increase of 163.80% [1] - Total profit was reported at 1.509 billion yuan, which is a year-on-year growth of 162.22% [1] - The net profit attributable to shareholders was 1.136 billion yuan, reflecting a year-on-year increase of 76.80% [1] - Basic earnings per share increased by 77.39% year-on-year [1] - The weighted average return on net assets rose by 2.59 percentage points compared to the previous year [1] Factors Influencing Profit Growth - The profit growth was primarily driven by a reduction in asset impairment provisions for goodwill and intangible assets, which decreased by 686 million yuan year-on-year [1] - Additionally, adjustments in store operations led to a decline in fixed costs such as labor and rent [1]

Core Viewpoint - China National Pharmaceutical Group (国药控股) announced the preliminary performance report for China National Pharmaceutical Group Co., Ltd. (国药一致) for the fiscal year 2025, highlighting a mixed performance with a slight decline in revenue but significant growth in profits [1] Financial Performance Summary - The total operating revenue for China National Pharmaceutical Group Co., Ltd. reached 73.416 billion RMB, representing a year-on-year decrease of 1.29% [1] - Operating profit amounted to 1.513 billion RMB, showing a substantial year-on-year increase of 163.80% [1] - Total profit for the period was 1.509 billion RMB, which is a year-on-year growth of 162.22% [1] - Net profit attributable to shareholders was 1.136 billion RMB, reflecting a year-on-year increase of 76.80% [1] - Basic earnings per share increased by 77.39% year-on-year [1] - The weighted average return on equity rose by 2.59 percentage points compared to the previous year [1] Factors Contributing to Profit Growth - The profit growth was primarily driven by a reduction in asset impairment provisions for goodwill and intangible assets, which decreased by 686 million RMB year-on-year [1] - Additionally, adjustments in store operations led to a decrease in fixed costs such as labor and rent [1]

Core Viewpoint - NEBIUS (NBIS.US) experienced a decline of 9.3%, closing at $117.73, following the announcement of plans to raise $3.75 billion through convertible bonds [1] Group 1: Fundraising Plans - The company intends to utilize the net proceeds from the bond issuance to support ongoing business growth [1] - Specific allocations for the funds include expenditures related to data center construction and expansion, investment in the development of a full-stack AI cloud platform, and procurement of key components [1] - Additionally, the funds will be used for general corporate purposes [1]

Group 1 - BlackRock, Inc. increased its stake in Kunlun Energy (00135.HK) by purchasing 4.83237 million shares at an average price of HKD 8.2917 per share, totaling approximately HKD 40.0686 million [1] - Following this transaction, BlackRock's total holdings in Kunlun Energy rose to 434,681,051 shares, increasing its ownership percentage from 4.96% to 5.02% [1][3]

Core Viewpoint - Hengding Industrial (01393.HK) announced that it will hold a board meeting on March 31, 2026, to approve the annual performance for the year ending December 31, 2025, and to consider the payment of a final dividend, if any [1] Group 1 - The board meeting is scheduled for March 31, 2026 [1] - The meeting will focus on approving the annual performance of the company and its subsidiaries for the year ending December 31, 2025 [1] - The board will also consider the payment of a final dividend, subject to approval [1]

Core Viewpoint - Anzhiqiang has submitted his resignation as the Deputy General Manager of Beijing Jinyu Group Co., Ltd. due to retirement, and he will not hold any other positions within the company after his resignation [1] Company Summary - The resignation was officially received by the board of directors on March 17, 2026 [1]

Group 1 - The three major U.S. stock indices opened higher, with the Nasdaq up 0.37%, the S&P 500 up 0.46%, and the Dow Jones up 0.69% [1] - Nvidia's stock rose over 1% as CEO Jensen Huang raised the revenue forecast for its 2027 computing chip to $1 trillion [1] - Micron Technology's stock increased by over 2%, with its HBM4 production line having commenced mass production and shipping in the first quarter, receiving a price target increase to $525 from RBC [1] - Uber's stock surged over 4% as the company plans to launch a global fleet of autonomous vehicles powered by Nvidia's Level 4 software in the first half of next year [1]

Group 1 - Norges Bank increased its stake in 康龙化成 (03759.HK) by purchasing 557,500 shares at an average price of HKD 19.5974 per share, totaling approximately HKD 10.93 million [1] - Following the acquisition, Norges Bank's total shareholding in 康龙化成 rose to 24,944,324 shares, increasing its ownership percentage from 6.91% to 7.07% [1]

Core Viewpoint - The announcement indicates that the company, Reading Group (00772.HK), is renewing its copyright cooperation framework agreement with Tencent, which will extend the partnership until December 31, 2029, pending independent shareholder approval [1] Group 1: Copyright Cooperation Agreement - The renewal of the copyright cooperation framework agreement is set to take effect from January 1, 2027, and will last for three years until December 31, 2029 [1] - The agreement is part of the company's ongoing business operations and aims to enhance collaboration in copyright-related transactions [1] Group 2: Advertising Cooperation Agreement - The board anticipates that the existing annual cap under the 2025 advertising cooperation framework agreement will be insufficient to meet the company's business development needs [1] - A new advertising cooperation framework agreement is to be established on March 17, 2026, which will set annual caps for three years until December 31, 2028, also subject to independent shareholder approval [1] - The 2025 advertising cooperation framework agreement will automatically terminate and become invalid upon the effectiveness of the 2026 agreement [1]